(Q38555292)

4 September 2017

title

Poly(alkyl cyanoacrylate) nanocapsules as a delivery system in the rat for octreotide, a long-acting somatostatin analogue (English)

1 reference

4 September 2017

Damgé C

1

1 reference

4 September 2017

Vonderscher J

series ordinal

2

1 reference

4 September 2017

Marbach P

series ordinal

3

1 reference

4 September 2017

Pinget M

series ordinal

4

1 reference

4 September 2017

publication date

1 October 1997

1 reference

Journal of Pharmacy and Pharmacology

4 September 2017

published in

1 reference

4 September 2017

volume

49

1 reference

4 September 2017

issue

10

1 reference

4 September 2017

page(s)

949-954

1 reference

Transmucosal passage of polyalkylcyanoacrylate nanocapsules as a new drug carrier in the small intestine

4 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.1997.TB06022.X

Somatostatin analogue octreotide and inhibition of tumour growth in metastatic endocrine gastroenteropancreatic tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.1997.TB06022.X

SMS 201–995: A very potent and selective octapeptide analogue of somatostatin with prolonged action

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.1997.TB06022.X

Somatostatin and somatostatin analogues: pharmacokinetics and pharmacodynamic effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.1997.TB06022.X

Degradation of poly (isobutyl cyanoacrylate) nanoparticles

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.1997.TB06022.X

Effect of octreotide on blood glucose and counterregulatory hormones in insulin-dependent diabetic patients: the role of dose and route of administration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.1997.TB06022.X

The Effect of Site of Administration in the Gastrointestinal Tract on the Absorption of Insulin from Nanocapsules in Diabetic Rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.1997.TB06022.X

Somatostatin (second of two parts).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.1997.TB06022.X

21 January 2018

Somatostatin and cancer

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.1997.TB06022.X

Long-term treatment of 189 acromegalic patients with the somatostatin analog octreotide. Results of the International Multicenter Acromegaly Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.1997.TB06022.X

Highly active cyclic and bicyclic somatostatin analogues of reduced ring size

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.1997.TB06022.X

Somatostatin analogs for diagnosis and treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.1997.TB06022.X

Effective and lasting growth-hormone suppression in active acromegaly with oral administration of somatostatin analogue SMS 201-995.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.1997.TB06022.X

Effect of the somatostatin analogue sandostatin (SMS 201-995) on gastrointestinal, pancreatic and biliary function and hormone release in normal men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.1997.TB06022.X

Effect of 4 weeks of octreotide treatment on prolactin, thyroid stimulating hormone and thyroid hormones in acromegalic patients. A double blind placebo-controlled cross-over study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.1997.TB06022.X

A potent cyclic hexapeptide analogue of somatostatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2042-7158.1997.TB06022.X

10.1111/J.2042-7158.1997.TB06022.X

21 January 2018

Identifiers

DOI

1 reference

4 September 2017

1 reference